India · Delayed Price · Currency is INR Zensar Technologies Earnings Call Transcripts
Fiscal Year 2026
-
Revenue and profitability reached record highs in FY 2026, driven by AI-native offerings and a mega deal win. TMT remains under pressure, but strong order book and disciplined execution support a positive outlook for FY 2027.
-
Q3 FY26 saw modest revenue growth and strong margin expansion, driven by offshore volume and disciplined execution. BFSI led growth, while TMT and Healthcare faced headwinds. AI initiatives and a robust cash position support ongoing investments and shareholder returns.
-
Q2 FY26 saw steady revenue and margin growth, with strong performance in BFS, healthcare, and AI-driven services, while TMT faced secular headwinds. The company maintained robust cash reserves, improved utilization, and increased AI-influenced order bookings to 28%.
-
Revenue grew 3.3% sequentially to $162M, with strong AI-driven deal momentum and improved attrition. EBITDA margin declined to 15.2% due to higher costs, while order bookings rose 11.7% YoY. Management projects continued growth but notes macro headwinds and margin pressures from wage hikes and ESOPs.
Fiscal Year 2025
-
Q4 FY25 delivered revenue growth, margin expansion, and a robust order book despite macro uncertainty. BFSI and TMT segments performed well, while manufacturing and healthcare saw declines. Management maintains a mid-teens margin outlook and increased dividend payout.
-
Q3 FY25 delivered 8.6% YoY revenue growth and record order bookings, with gross margin up 200 bps and EBITDA at 15.6%. MCS and Healthcare segments grew, while TMT declined. Management remains optimistic for double-digit growth in FY26 despite macro uncertainties.
-
Order book reached a record $201.8M, with Q2 revenue up 4% YoY and 1.2% sequentially. BFSI and healthcare led growth, while TMT declined. Margins remained stable, and offshore revenue share rose to 50%.